Clovis Oncology, Inc. (CLVS) Holdings Maintained by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank continued to hold its position in Clovis Oncology, Inc. (NASDAQ:CLVS) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,819 shares of the biopharmaceutical company’s stock at the end of the second quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Clovis Oncology were worth $170,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. raised its holdings in shares of Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 1,168 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Clovis Oncology by 3.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 100 shares during the period. Quantbot Technologies LP purchased a new position in shares of Clovis Oncology in the 1st quarter worth about $185,000. Ameritas Investment Partners Inc. purchased a new position in shares of Clovis Oncology in the 1st quarter worth about $195,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Clovis Oncology in the 1st quarter worth about $204,000. Institutional investors own 99.03% of the company’s stock.
A number of equities analysts have recently commented on the company. BidaskClub downgraded Clovis Oncology from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 9th. Morgan Stanley restated an “overweight” rating and issued a $93.00 price objective on shares of Clovis Oncology in a report on Thursday, August 10th. Cann restated a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Finally, Leerink Swann cut their price objective on Clovis Oncology to $107.00 and set an “outperform” rating on the stock in a report on Friday, August 18th. Nine research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $84.91.
In related news, Director James C. Blair sold 18,450 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the transaction, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $91.56, for a total value of $274,680.00. Following the transaction, the insider now directly owns 197,583 shares of the company’s stock, valued at approximately $18,090,699.48. The disclosure for this sale can be found here. Insiders have sold a total of 24,450 shares of company stock valued at $1,935,185 in the last three months. 17.40% of the stock is owned by insiders.
Shares of Clovis Oncology, Inc. (CLVS) opened at 69.46 on Monday. The firm’s market cap is $3.40 billion. The firm’s 50-day moving average price is $74.21 and its 200-day moving average price is $68.78. Clovis Oncology, Inc. has a 52 week low of $25.50 and a 52 week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.02). The business had revenue of $14.62 million during the quarter, compared to the consensus estimate of $13.07 million. During the same period in the prior year, the company earned ($2.07) earnings per share. Clovis Oncology’s revenue was down 32.5% on a year-over-year basis. Equities research analysts expect that Clovis Oncology, Inc. will post ($7.56) EPS for the current fiscal year.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.